Intelligence · Clinical Pipeline
Telethon Foundation Pipeline
All ClinicalTrials.gov programs at Telethon Foundation — phase, modality, and trial IDs.
- Programs
- 3
Quick answer
Telethon Foundation has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
Fondazione Telethon ETS
High-Risk, Surgically Resectable Melanoma
1 trial -
A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments.
Fondazione Telethon ETS
Hepatocellular carcinoma
1 trial -
Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.
Fondazione Telethon ETS
Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry
1 trial
Frequently asked questions
How many pipeline programs does Telethon Foundation have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs